Skip to content
DraconiticResearch
Search Sources API
220,595 studies31 sourcesUpdated 34 min ago

Oncology

5,778 studies502 in 7 days2,682 in 30 days

Filters
Type
Date
Clear

Latest

5,778 studies

  1. OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
    Christoph Schultheiß, Brenda Besemer, Edith Willscher +21
    Communications MedicinePeer-reviewedCC BY 4.0Full textOncologyPMC
  2. Dosimetric Characterization and Workflow Optimization of the FLASH-SARRP for Reliable Preclinical Radiobiological Studies
    M. Knol, P. Goncalves Jorge, L. V. Kunz +7
    bioRxivPreprintCC BYFull textOncologybioRxiv
  3. Deep Fascia Plane Dissection and Mattox Maneuver for Lymphadenectomy in Pancreatic Body-Tail Cancer: SEER-Based Evidence, Anatomical Rationale, and Quantitative Modeling
    X. Ye, Y. Wang, W. Yang +4
    medRxivPreprintCC BYFull textOncologymedRxiv
  4. The alternative NF-κB RelB subunit is a novel critical sensor of lipid metabolism to promote tumor development
    T. Becquard, C. Benatar, C. Bretot +20
    Cell Death and DiseasePeer-reviewedCC BY 4.0Full textOncologyHAL
  5. Solitary Skull Metastasis as Initial Presentation of Hepatocellular Carcinoma: A Rare Case Report and Management Review
    Ashish Chugh, Dipti Patil, Prashant Punia +1
    Annals of African MedicinePeer-reviewedCC BY-NC-SA 4.0Full textOncologyPMC
  6. Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
    Kozo Kataoka, Kazuma Ito, Yoshiaki Nakamura +35
    JAMA OncologyPeer-reviewedLicence not stated11 citedOncologyOpenAlex
  7. Pan-cancer analysis of tissue-plasma genomic concordance reveals enhanced concordance with liver metastasis and plasma clonality as predictor of poorer overall survival
    Meng Zhang, Yi Feng, Xue Du +12
    NPJ Precision OncologyPeer-reviewedCC BY 4.0Full textOncologyPMC
  8. Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance
    Yali Hu, Jingyao Ge, Meiqi Xin +3
    Cancer LettersPeer-reviewedCC BY14 citedOncologyOpenAlex
  9. Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
    Leonardo Brunetti, Valentina Santo, David James Pinato +27
    The Lancet OncologyPeer-reviewedCC BY9 citedOncologyOpenAlex
  10. Generalizable AI predicts immunotherapy outcomes across cancers and treatments
    Wan Xiang Shen, Intae Moon, Thinh H. Nguyen +5
    Nature MedicinePeer-reviewedCC BY-NC-NDFull text34 citedOncologyOpenAlex
  11. WITHDRAWN: Multi-Timepoint Risk Stratification in Rare Cancers: A Computational Framework Validated against Published Ewing Sarcoma Trial Data
    J. Kress
    medRxivPreprintCC BYFull textOncologymedRxiv
  12. From tumor regression grading to interpretable endpoints in neoadjuvant oncology
    Cédric Schraepen, Albert Wolthuis, Wentao Tang +10
    NPJ Precision OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  13. Metabolic transcriptomic subtyping defines distinct immunogenomic and clinical landscapes in non–small cell lung cancer
    Seo-Young Lee, Heesun Cheong, Seog-Yun Park +3
    NPJ Precision OncologyPeer-reviewedCC BY-NC-ND 4.0Full text1 citedOncologyPMC
  14. Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study
    Yeong Hak Bang, Dawon Kang, Seungwon Lee +22
    NPJ Precision OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  15. Outcomes Based on Age in CALGB 140503 (Alliance): Lobar vs. Sublobar Resection for Peripheral Stage IA Non–Small Cell Lung Cancer
    Apar Kishor Ganti, Bryce Damman, Xiaofei Wang +2
    Clinical lung cancerPeer-reviewedLicence not statedFull textOncologyPMC
  16. Patterning human kidney organoids with synthetic Wnt-secreting organizers
    Connor C. Fausto, Fokion Glykofrydis, Navneet Kumar +15
    SciencePeer-reviewedCC BY14 citedOncologyOpenAlex
  17. Human cancer genomes harbor the mutational signature of tobacco-specific nitrosamines NNN and NNK
    Michael Korenjak, Nuri A. Temiz, Stéphane Keïta +24
    Genome MedicinePeer-reviewedCC BY-NC-ND10 citedOncologyOpenAlex
  18. PDLIM4 increases sphingolipid accumulation to promote cancer stem cell characteristics and chemotherapy resistance in colorectal cancer
    Yingqiu Song, Zhiyong Xiong, Dagui Zhou +13
    Communications BiologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyDOAJPMC
  19. Comprehensive analysis of mitochondrial metabolism–associated clusters and prognostic scoring model index construction in breast cancer
    Chen Wang, Xiaofan Wu, Jingkun Wang +5
    Scientific ReportsPeer-reviewedCC BYFull textOncologyDOAJ
  20. Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer
    Rianne D. W. Vaes, Zhongli Chen, Iris E. W. G. Laven +21
    NPJ Precision OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMCDOAJ
  21. Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies
    Chen-xi Zhao, Shu-yun Wang, Ke Li
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text2 citedOncologyPMC
  22. Tumor-targeted nanobubbles delivering PFP/siFGFR1 for US imaging and overcoming enzalutamide-resistant in prostate cancer
    Weimin Dong, Zhiming Zhang, Zhengming Su +7
    Cancer NanotechnologyPeer-reviewedCC BYFull textOncologyDOAJ
  23. Chromogranin B promotes EMT-associated stem-like properties and chemoresistance in HNSCC
    Zhongwan Li, Lie Yuan, Yu Jiang +7
    Journal of Translational MedicinePeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMCDOAJ
  24. Artificial intelligence (AI) in melanocytic lesions diagnosis: a systematic review of methods incorporating ABCD(E)-derived features
    Otto Muller Silva Lopes, Juliana Almeida Oliveira, Victor Brunno Alves Nogueira +5
    Journal of Cancer Research and Clinical OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMCDOAJ
  25. Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation.
    Lan Shen, Yibo Gao, Zhengbo Song +5
    BMC cancerPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJPMC